CinnaGen Company
CinnaGen Research and Production Company is a privately held Iranian biopharmaceutical manufacturer founded in 1994. It develops and produces biosimilars, recombinant medicines and other biological therapies from Karaj, supported by headquarters and regulatory operations in Tehran. The company matters as a domestic supplier of high-value biologics and a route to Iranian and export pharmaceutical markets.
Market position
CinnaGen is positioned as a major private biopharmaceutical and biosimilar manufacturer in Iran and the wider MENA region, with a substantial domestic presence across multiple biological-therapy areas.
Operations & footprint
Products and services
CinnaGen develops and manufactures biopharmaceuticals, biosimilars, recombinant proteins and specialty medicines across neurology and ophthalmology, oncology and hematology, endocrinology and infertility, autoimmune and immunology, rare metabolic and genetic diseases, and infectious diseases. Its activities include biotechnology research, cell-line and recombinant-product development, manufacturing, clinical development, regulatory affairs, technology transfer and international commercialization.
Operations and assets
The company’s main biomanufacturing site is in Simin Dasht Industrial Area, Karaj/Fardis, Alborz Province. Facilities include mammalian cell culture, microbial fermentation, protein-purification suites, cleanrooms, lyophilisation, pre-filled-syringe filling and automated quality-control laboratories. Tehran hosts headquarters and regulatory functions.
Geographic footprint
Iranian operations are centred on Tehran and Karaj/Fardis in Alborz Province. The group also has a manufacturing presence in Turkey through CinnaGen Ilac and distributes into CIS markets, the Middle East, North Africa, South Asia and Latin America.
Ownership & group structure
Ownership
Privately held, founded by Iranian biotechnology researchers and private investors. The company operates within the broader CinnaGen Group ecosystem.
Parent company
Independent private enterprise within CinnaGen Group (گروه دارویی سیناژن).
Subsidiaries and group companies
AryoGen Pharmed; Orchid Pharmed (Orchipharm); NanoHayat Darou; CinnaGen Ilac, Turkey.
Reported scale
Employees: Approximately 500–1,000 direct employees; 1,000–5,000 employees across CinnaGen and affiliated group companies.
Commercial and investment relevance
CinnaGen is relevant for investors assessing Iran's biotechnology capabilities, biosimilar manufacturing, specialty-drug localization, pharmaceutical exports, R&;D intensity and technology transfer. Due diligence should examine product registrations by jurisdiction, manufacturing quality systems, GMP status, clinical and comparability evidence, IP and licensing rights, export subsidiaries, international manufacturing sites, regulatory inspections, pharmacovigilance, raw-material and single-use-system dependence, foreign currency requirements and the independence and quality of clinical evidence supporting individual products. CinnaGen is a key supplier of locally manufactured biological therapies in Iran, reducing reliance on imported specialty medicines. For distributors, suppliers and partners, it is a significant route to Iran’s biosimilar market and selected export destinations.
Constraints, risk & compliance
Key risks and constraints
Production depends on specialised imported bioprocess inputs and analytical equipment, including single-use systems, cell-culture media, purification resins and filters. Export-control delays and restricted cross-border settlement can disrupt procurement, licensing payments and international expansion. Domestic medicine price controls can also compress margins when imported input costs rise.
Sanctions and compliance considerations
CinnaGen was not listed as a primary entity on the US OFAC SDN list materials reviewed in March 2025. Transactions involving Iranian banking, imported bioprocess inputs, technology transfers and cross-border payments remain subject to sanctions and export-control screening.
Need more than a public profile?
Ask Hormuz to investigate, verify or act locally around CinnaGen Company. Tell us exactly what you need.
Connected Intelligence
Relevant geography, industry, market and execution context for this profile.
Frequently asked questions
Direct answers to the questions most likely to arise when reviewing this profile.
What does CinnaGen manufacture?
CinnaGen manufactures biopharmaceuticals, including biosimilars and recombinant medicines for areas such as multiple sclerosis, anemia, autoimmune disease, infertility, osteoporosis and oncology supportive care.
Where are CinnaGen’s main operations located?
Its headquarters and regulatory centre are in Tehran, while its main biomanufacturing facilities are in the Simin Dasht Industrial Area in Karaj/Fardis, Alborz Province.
Is CinnaGen publicly listed?
No. CinnaGen Research and Production Company is privately held.
Why is CinnaGen commercially important in Iran?
The company supplies locally manufactured biological therapies that reduce dependence on imported specialty medicines and supports pharmaceutical exports from Iran.